AU2013251345B2 - Pantothenate derivatives for the treatment of neurologic disorders - Google Patents

Pantothenate derivatives for the treatment of neurologic disorders Download PDF

Info

Publication number
AU2013251345B2
AU2013251345B2 AU2013251345A AU2013251345A AU2013251345B2 AU 2013251345 B2 AU2013251345 B2 AU 2013251345B2 AU 2013251345 A AU2013251345 A AU 2013251345A AU 2013251345 A AU2013251345 A AU 2013251345A AU 2013251345 B2 AU2013251345 B2 AU 2013251345B2
Authority
AU
Australia
Prior art keywords
compound
subject
substituted
unsubstituted
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013251345A
Other languages
English (en)
Other versions
AU2013251345A1 (en
Inventor
Marek BIESTEK
Martin SHKRELI
Andrew Vaino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travere Therapeutics Inc
Original Assignee
Retrophin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrophin Inc filed Critical Retrophin Inc
Publication of AU2013251345A1 publication Critical patent/AU2013251345A1/en
Assigned to Retrophin, Inc. reassignment Retrophin, Inc. Request for Assignment Assignors: BIESTEK, Marek, Retrophin, Inc., SHKRELI, Martin, VAINO, ANDREW
Application granted granted Critical
Publication of AU2013251345B2 publication Critical patent/AU2013251345B2/en
Priority to AU2017239508A priority Critical patent/AU2017239508C1/en
Priority to AU2019219733A priority patent/AU2019219733A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013251345A 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders Ceased AU2013251345B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017239508A AU2017239508C1 (en) 2012-04-27 2017-10-04 Pantothenate derivatives for the treatment of neurologic disorders
AU2019219733A AU2019219733A1 (en) 2012-04-27 2019-08-20 Pantothenate derivatives for the treatment of neurologic disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639602P 2012-04-27 2012-04-27
US61/639,602 2012-04-27
PCT/US2013/038458 WO2013163576A1 (en) 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017239508A Division AU2017239508C1 (en) 2012-04-27 2017-10-04 Pantothenate derivatives for the treatment of neurologic disorders

Publications (2)

Publication Number Publication Date
AU2013251345A1 AU2013251345A1 (en) 2014-11-27
AU2013251345B2 true AU2013251345B2 (en) 2017-08-31

Family

ID=48428654

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013251345A Ceased AU2013251345B2 (en) 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders
AU2017239508A Ceased AU2017239508C1 (en) 2012-04-27 2017-10-04 Pantothenate derivatives for the treatment of neurologic disorders
AU2019219733A Abandoned AU2019219733A1 (en) 2012-04-27 2019-08-20 Pantothenate derivatives for the treatment of neurologic disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017239508A Ceased AU2017239508C1 (en) 2012-04-27 2017-10-04 Pantothenate derivatives for the treatment of neurologic disorders
AU2019219733A Abandoned AU2019219733A1 (en) 2012-04-27 2019-08-20 Pantothenate derivatives for the treatment of neurologic disorders

Country Status (24)

Country Link
US (3) US8673883B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP3489248A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP6254151B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150035550A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN106977544B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2013251345B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014026817A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2879314A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1118198T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3112372T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2708813T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20161389T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE029474T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09584A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (2) LT2841438T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX360149B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL3112372T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2841438T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS55319B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2018112720A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI3112372T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (2) SMT201900007T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR201819263T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013163576A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364263B2 (en) 2015-12-08 2019-07-30 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
US10407447B2 (en) 2013-10-25 2019-09-10 Retrophin, Inc. Pantothenate derivatives for the treatment of neurological disorders

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161389T1 (hr) * 2012-04-27 2016-12-02 Retrophin, Inc. Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
EP2868662A1 (en) * 2013-11-04 2015-05-06 Acies Bio d.o.o. Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
WO2018148313A1 (en) * 2017-02-07 2018-08-16 Retrophin, Inc. Solid fosmetpantotenate formulations
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676976A (en) 1950-12-04 1954-04-27 Nat Res Dev Synthesis of pantothenic acid-4' phosphate
US2870188A (en) 1955-10-03 1959-01-20 Hoffmann La Roche Process for the manufacture of pantothenic acid 4'-phosphate and its salts
RU2002110463A (ru) * 1999-09-21 2004-02-27 Басф Акциенгезелльшафт (De) Способ и микроорганизмы для получения пантосоединений
WO2003008626A2 (en) 2001-07-20 2003-01-30 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
JP2005531326A (ja) * 2002-07-03 2005-10-20 ビーエーエスエフ アクチェンゲゼルシャフト パントテン酸の高生産のための微生物及び方法
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
HRP20161389T1 (hr) * 2012-04-27 2016-12-02 Retrophin, Inc. Derivati pantotenata namijenjeni liječenju neuroloških poremećaja

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAYFLICK, S.J. "Unravelling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name…" CURRENT OPINION IN PEDIATRICS (2003) Vol.15 No.6 pages 572 to 577 *
HECKER, S.J. et al. "Prodrugs of Phosphates and Phosphonates" JOURNAL OF MEDICINAL CHEMISTRY (2008) Vol.51 No.8 pages 2328 to 2345 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407447B2 (en) 2013-10-25 2019-09-10 Retrophin, Inc. Pantothenate derivatives for the treatment of neurological disorders
US10364263B2 (en) 2015-12-08 2019-07-30 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Also Published As

Publication number Publication date
CN104520307A (zh) 2015-04-15
EP3112372A1 (en) 2017-01-04
US9181286B2 (en) 2015-11-10
AU2017239508B2 (en) 2019-05-23
SMT201600395B (it) 2017-01-10
AU2019219733A1 (en) 2019-09-05
DK3112372T3 (en) 2019-02-18
RU2653497C2 (ru) 2018-05-10
CN106977544A (zh) 2017-07-25
JP2015515496A (ja) 2015-05-28
JP2017141257A (ja) 2017-08-17
BR112014026817A2 (pt) 2017-07-18
HK1207863A1 (en) 2016-02-12
EP3112372B1 (en) 2018-11-07
RS58336B1 (sr) 2019-03-29
PL3112372T3 (pl) 2019-05-31
PL2841438T3 (pl) 2017-08-31
HUE042199T2 (hu) 2019-06-28
IN2014DN09584A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-17
RS55319B1 (sr) 2017-03-31
CN106977544B (zh) 2019-06-07
PT3112372T (pt) 2019-01-17
LT2841438T (lt) 2016-11-10
CA2879314A1 (en) 2013-10-31
DK2841438T3 (en) 2016-11-28
AU2017239508C1 (en) 2019-11-07
AU2013251345A1 (en) 2014-11-27
SI3112372T1 (sl) 2019-04-30
JP6560284B2 (ja) 2019-08-14
WO2013163576A1 (en) 2013-10-31
CY1121238T1 (el) 2020-05-29
HRP20161389T1 (hr) 2016-12-02
ES2600179T3 (es) 2017-02-07
SI2841438T1 (sl) 2016-12-30
US20130289001A1 (en) 2013-10-31
RU2018112720A (ru) 2019-02-28
US9629862B2 (en) 2017-04-25
EP2841438B1 (en) 2016-08-10
AU2017239508A1 (en) 2017-10-26
JP6254151B2 (ja) 2017-12-27
TR201819263T4 (tr) 2019-01-21
HRP20190038T1 (hr) 2019-02-22
HUE029474T2 (en) 2017-02-28
EP2841438A1 (en) 2015-03-04
JP2019206553A (ja) 2019-12-05
CY1118198T1 (el) 2017-06-28
LT3112372T (lt) 2019-01-10
US8673883B2 (en) 2014-03-18
ES2708813T3 (es) 2019-04-11
MX2014013048A (es) 2015-04-10
KR20150035550A (ko) 2015-04-06
MX360149B (es) 2018-10-24
RU2014147739A (ru) 2016-06-20
CN104520307B (zh) 2016-12-21
SMT201900007T1 (it) 2019-02-28
PT2841438T (pt) 2016-11-22
US20160015727A1 (en) 2016-01-21
AU2017239508B9 (en) 2019-06-13
EP3489248A1 (en) 2019-05-29
US20140135294A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
AU2017239508B2 (en) Pantothenate derivatives for the treatment of neurologic disorders
US10407447B2 (en) Pantothenate derivatives for the treatment of neurological disorders
AU2014343730B2 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (PKAN) and methods for the synthesis of such compounds
AU2014343730A1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (PKAN) and methods for the synthesis of such compounds
HK1232544A1 (en) Pantothenate derivatives for the treatment of neurologic disorders
HK1232544B (en) Pantothenate derivatives for the treatment of neurologic disorders
HK1207863B (en) Pantothenate derivatives for the treatment of neurologic disorders

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RETROPHIN, INC.

Free format text: FORMER APPLICANT(S): BIESTEK, MAREK; RETROPHIN, INC.; VAINO, ANDREW; SHKRELI, MARTIN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired